Management of Recurrent or Relapsed Cryptococcal Meningitis
For recurrent or relapsed cryptococcal meningitis, reinstitute the full induction phase of primary therapy for a prolonged course of 4-10 weeks, using combination therapy with a polyene (amphotericin B deoxycholate 0.7-1.0 mg/kg/day IV or liposomal amphotericin B 3-6 mg/kg/day IV) plus flucytosine (100 mg/kg/day orally in 4 divided doses). 1
Critical First Steps: Define True Relapse vs. IRIS
Before altering antifungal therapy, you must distinguish between:
- True microbiological relapse: Recovery of viable Cryptococcus from a previously sterile body site (CSF culture positive) PLUS recrudescence of clinical signs/symptoms 1
- IRIS (Immune Reconstitution Inflammatory Syndrome): Worsening symptoms without positive cultures, typically occurring 2-10 weeks after starting HAART in HIV patients 1, 2
Key distinction: Changing antigen titers, positive India ink results, or abnormal CSF chemistries alone are insufficient to diagnose relapse—you need positive cultures 1. IRIS does not require changes to antifungal therapy, only management of inflammation 1.
Root Cause Analysis
Most relapses stem from:
- Inadequate primary therapy (insufficient dose or duration) 1
- Poor compliance with consolidation/maintenance fluconazole 1
- Failure to optimize immune status 1
- Inadequate intracranial pressure management 1
Treatment Algorithm for Confirmed Relapse
Step 1: Optimize Host Factors (Critical)
- HIV patients: Ensure HAART is optimized; if not started, initiate 2-10 weeks after antifungal therapy begins 1
- Transplant patients: Reduce immunosuppressants to the lowest tolerable level 1
- All patients: Aggressively manage elevated intracranial pressure with serial lumbar punctures (target opening pressure <20 cm H₂O) 1
Step 2: Reinduction Therapy
Primary recommendation:
- Amphotericin B deoxycholate 0.7-1.0 mg/kg/day IV (or up to 1 mg/kg if initial dose was ≤0.7 mg/kg) 1
- OR Liposomal amphotericin B 3-6 mg/kg/day IV (increase to 6 mg/kg for high fungal burden or treatment failure) 1
- PLUS Flucytosine 100 mg/kg/day orally in 4 divided doses 1
- Duration: 4-10 weeks (longer than initial induction) 1
Alternative for polyene-intolerant patients:
- Fluconazole ≥800 mg/day orally PLUS flucytosine 100 mg/kg/day orally 1
Alternative for flucytosine-intolerant patients:
- Amphotericin B deoxycholate 0.7 mg/kg/day IV PLUS fluconazole 800 mg/day orally 1
Step 3: Consolidation and Maintenance
After completing reinduction:
- Consolidation: Fluconazole 400-800 mg/day orally for 8 weeks 1
- Maintenance: Fluconazole 200 mg/day orally 1
For HIV patients with immune reconstitution:
- Continue maintenance until CD4 count >100 cells/μL and undetectable/very low HIV RNA for ≥3 months (minimum 12 months total antifungal therapy) 1, 3
- Reinstitute maintenance if CD4 drops <100 cells/μL 1
Special Considerations
Intracranial Pressure Management
- Measure opening pressure at every lumbar puncture 1
- If elevated (>25 cm H₂O), drain CSF to reduce pressure by 50% or to <20 cm H₂O 1
- Repeat daily until pressure normalizes 1
- If persistently elevated despite frequent drainage, consider VP shunt placement 1
- Avoid acetazolamide and corticosteroids for pressure management (reserved for IRIS treatment only) 1
IRIS Management (If Applicable)
- Do not alter antifungal therapy 1
- Minor manifestations resolve spontaneously in days to weeks 1
- For major CNS inflammation with increased intracranial pressure: Consider corticosteroids (prednisone 0.5-1.0 mg/kg/day or higher-dose dexamethasone for severe symptoms) for 2-6 weeks 1
Monitoring During Retreatment
- Repeat lumbar puncture after 2 weeks to assess CSF sterilization 1
- Monitor opening pressures if symptoms persist 1
- Check flucytosine levels (target 30-80 μg/mL) and monitor for hematologic toxicity 1
- Monitor renal function closely with amphotericin B 1
Common Pitfalls
- Treating based on antigen titers alone: Persistently positive or rising cryptococcal antigen without positive cultures does not mandate treatment escalation 1
- Misdiagnosing IRIS as relapse: This leads to unnecessary antifungal intensification when anti-inflammatory therapy is needed 2
- Inadequate pressure management: Failure to aggressively control intracranial pressure is a major cause of morbidity and mortality 1
- Premature discontinuation of maintenance therapy: Especially in HIV patients before adequate immune reconstitution 1, 3
The evidence strongly supports that relapse rates in non-HIV patients historically ranged 15-25%, primarily in the first year, which has decreased with fluconazole maintenance therapy 1. The key to successful retreatment is longer, more intensive therapy combined with meticulous attention to immune optimization and intracranial pressure control.